
HealthEquity (HQY) Stock Forecast & Price Target
HealthEquity (HQY) Analyst Ratings
Bulls say
HealthEquity is a promising company due to its strong HSA business and potential for market expansion. Despite a lowered price target, it is still projected to have a 40% upside, supported by its 20.7% increase in gross profit and improved gross margin. With its solid adjusted EBITDA and net income, along with a focus on becoming a leader in health-tech and services, HealthEquity is expected to surpass expectations and outperform in the future. The company also showed strong third quarter results with growth in revenue and gross margin, as well as significant growth in custodial revenue and client-held funds. Overall, HealthEquity is a financially stable company with a positive financial outlook, making it a strong choice for investors.
Bears say
HealthEquity is facing increasing competition in the healthcare savings industry and has experienced lower average service fees per account. While they have managed to decrease service costs through technological investments, it is not enough to offset the decrease in fees, leading to a decrease in gross margins. Additionally, with a high Long-term debt of $957.4 million, the company may struggle to generate enough cash flow to pay down its debt over time.
This aggregate rating is based on analysts' research of HealthEquity and is not a guaranteed prediction by Public.com or investment advice.
HealthEquity (HQY) Analyst Forecast & Price Prediction
Start investing in HealthEquity (HQY)
Order type
Buy in
Order amount
Est. shares
0 shares